Pharmaceuticals
Bioton?s SciGen Ltd. announces contract
in China
Singapore-based SciGen Ltd., a biotech start-up part-owned by Poland?s Bioton group, said it has signed a hepatitis B vaccine distribution agreement with China?s Hefei Life Science Park Investment & Development Co. The order for hepatitis B vaccine is worth at least 145 million dollars over a period of seven years, SciGen said. Bioton officials were not available to comment on the deal. Polish firm is the biggest shareholder of SciGen, with a 25 percent stake. It said recently it would buy another 18.6 percent from other shareholders.
Home appliances
Amica slumps on sales warning
...